Synergic Effect of Genotype Changes in Pertussis Toxin and Pertactin on Adaptation to an Acellular Pertussis Vaccine in the Murine Intranasal Challenge Model
- 1 May 2010
- journal article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 17 (5) , 807-812
- https://doi.org/10.1128/cvi.00449-09
Abstract
The Bordetella pertussis pertussis toxin and pertactin (Prn) are protective antigens and are contained in acellular pertussis vaccines. Polymorphisms in the A subunit of pertussis toxin (PtxA) and pertactin have been proposed to mediate vaccine resistance and contribute to pertussis reemergence. To test this hypothesis, previous studies compared clinical isolates expressing different alleles for the proteins. However, other virulence factors or virulence factor expression levels also may vary, confounding the analysis. To overcome these limitations, we constructed isogenic mutants of B. pertussis Tohama expressing the alleles ptxA1 or ptxA2 and prn1 or prn2 and compared the efficacies of an acellular pertussis vaccine against the mutants in a mouse model. While the vaccine was effective against all of the B. pertussis strains regardless of the allele expression pattern, the strain expressing ptxA1 and prn2 displayed a survival advantage over the other strains. These results suggest that an allele shift to the ptxA1 prn2 genotype may play a role in the emergence of pertussis in vaccinated populations.Keywords
This publication has 34 references indexed in Scilit:
- Changes in Genetic Diversity of the Bordetella pertussis Population in the United Kingdom between 1920 and 2006 Reflect Vaccination Coverage and Emergence of a Single Dominant Clonal TypeJournal of Clinical Microbiology, 2009
- Pulsed-Field Gel Electrophoresis, Pertactin, Pertussis Toxin S1 Subunit Polymorphisms, and Surfaceome Analysis of Vaccine and Clinical Bordetella pertussis StrainsClinical and Vaccine Immunology, 2007
- Effect of Different Forms of Adenylate Cyclase Toxin ofBordetella pertussison Protection Afforded by an Acellular Pertussis Vaccine in a Murine ModelInfection and Immunity, 2006
- Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960Efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolatesVaccine, 2004
- Temporal Expression of Pertussis Toxin and Ptl Secretion Proteins byBordetella pertussisJournal of Bacteriology, 2004
- Bordetella pertussisProtein Pertactin Induces Type‐Specific Antibodies: One Possible Explanation for the Emergence of Antigenic Variants?The Journal of Infectious Diseases, 2003
- Evaluation of efficacy in terms of antibody levels and cell-mediated immunity of acellular pertussis vaccines in a murine model of respiratory infectionFEMS Immunology & Medical Microbiology, 2002
- Effect of Acellular Pertussis Vaccine Against Various Strains of Bordetella Pertussis in a Murine Model of Respiratory Infection.Journal of Health Science, 2002
- Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccinesVaccine, 1999
- Temporal Trends in the Population Structure ofBordetella pertussisduring 1949–1996 in a Highly Vaccinated PopulationThe Journal of Infectious Diseases, 1999